1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6940FCE7F13E4548685257F7F0072B6D8
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/940FCE7F13E4548685257F7F0072B6D8!OpenDocument
18
19OpenDocument
2035.172.224.102
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Marketing Management Marketing Strategy

Document Excerpt: Disease Awareness Program Excellence: Interview Narratives and Best Practices

DB Image

ID: MD-510


Features:

4 Info Graphics

15 Data Graphics

25 Metrics

12 Narratives


Pages/Slides: 4


Published: Pre-2017


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER

To download this excerpt, click "
Download Free Excerpt".

To return to the study abstract to purchase the full study
- click here

This excerpt includes research findings and metrics from document #5409 "Disease Awareness Program Excellence: Interview Narratives and Best Practices."

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Public Relations; Health Care; Biopharmaceutical


Companies Profiled:
Bayer; Abbvie; Genzyme; Adamas Pharmaceuticals; AstraZeneca; Biogen; Novartis; Eli Lilly; FleishmanHillard; Fresenius Medical Care AG & Co. KGaA; ZS Pharma; Indivior; Merck; Catalyst Pharmaceuticals; Prometheus Therapeutics & Diagnostics; Tokai Pharmaceuticals; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.